HCP, Hcp-2024 Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial 01 Aug View Fullscreen lungadmin First National Cancer Congress Malaysia NCSM Breaking Barriers In Cancer
